Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Raw chart and full-history price indicators begin at the captured split on Mar 26, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Mar 26, 2026.
Apimeds Pharmaceuticals US, Inc. subsidiary MindWave Innovations Inc. entered a two-year agreement with BlockAssure Inc. on October 4, 2026 to build and operate AssureChain for on-chain insurance and reinsurance, with quarterly development fees and 20% of AssureCoin.
Apimeds Pharmaceuticals US, Inc. appointed Eric Sherb as Chief Financial Officer effective October 1, 2026, succeeding Erick Frim’s immediate resignation as Interim Chief Financial Officer on September 29, 2026; Sherb’s base salary is $60,000 per year.
Apimeds Pharmaceuticals US, Inc. effected a one-for-ten reverse stock split effective as of 12:01 a.m. Eastern Time on July 24, 2026, reducing common stock par value from $0.01 per share to $0.001 per share.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Digital asset yield income | $282,732 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APUS
this stock
Apimeds Pharmaceuticals US, Inc.
|
$4.08M | — | — | — | 4.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.16B | +34.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$54.34B | +12.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.72B | +36.5% | +4.3% | 96.8 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Apimeds Pharmaceuticals US, Inc. subsidiary MindWave Innovations Inc. entered a two-year agreement with BlockAssure Inc. on October 4, 2026 to build and operate AssureChain for on-chain insurance and reinsurance, with quarterly development fees and 20% of AssureCoin.
ViewRaw-price comparisons begin at the captured split on Mar 26, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APUS | -10.1% | -46.1% | -81.9% | -10.1% | — |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -7.4% | -40.6% | -81.4% | -7.4% | — |
